Oreofe Olukemi Odejide, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hospice Care | 15 | 2023 | 678 | 3.770 |
Why?
|
Hematologic Neoplasms | 13 | 2024 | 1896 | 3.080 |
Why?
|
Terminal Care | 13 | 2024 | 1761 | 2.170 |
Why?
|
Hospices | 4 | 2023 | 245 | 2.090 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 1405 | 1.290 |
Why?
|
Palliative Care | 9 | 2024 | 3598 | 0.990 |
Why?
|
Bone Marrow Examination | 3 | 2016 | 155 | 0.910 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1374 | 0.660 |
Why?
|
Specimen Handling | 2 | 2014 | 702 | 0.640 |
Why?
|
Hematopoietic Stem Cell Transplantation | 9 | 2023 | 5672 | 0.600 |
Why?
|
Neoplasms | 9 | 2024 | 22173 | 0.570 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2020 | 237 | 0.560 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 2417 | 0.520 |
Why?
|
Multiple Myeloma | 3 | 2024 | 5146 | 0.470 |
Why?
|
Medicare | 7 | 2023 | 6770 | 0.460 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2013 | 40 | 0.450 |
Why?
|
Quality of Life | 9 | 2024 | 13367 | 0.420 |
Why?
|
Lymphoma, T-Cell | 1 | 2013 | 304 | 0.370 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1469 | 0.360 |
Why?
|
Transplantation, Autologous | 7 | 2023 | 2115 | 0.350 |
Why?
|
Lymphoma | 4 | 2022 | 1901 | 0.340 |
Why?
|
Cause of Death | 2 | 2017 | 3683 | 0.330 |
Why?
|
Physician-Patient Relations | 3 | 2023 | 3251 | 0.330 |
Why?
|
Medical Oncology | 3 | 2017 | 2321 | 0.320 |
Why?
|
Hodgkin Disease | 3 | 2022 | 1378 | 0.320 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 940 | 0.320 |
Why?
|
Health Services Accessibility | 2 | 2016 | 5440 | 0.310 |
Why?
|
Caregivers | 6 | 2023 | 2238 | 0.300 |
Why?
|
Radiotherapy | 1 | 2014 | 1498 | 0.290 |
Why?
|
Communication | 2 | 2019 | 3875 | 0.290 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1792 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11742 | 0.270 |
Why?
|
Depression | 2 | 2024 | 8126 | 0.260 |
Why?
|
Prognosis | 7 | 2023 | 29629 | 0.250 |
Why?
|
Isoquinolines | 3 | 2021 | 352 | 0.240 |
Why?
|
Humans | 55 | 2024 | 761596 | 0.240 |
Why?
|
SEER Program | 3 | 2018 | 1450 | 0.220 |
Why?
|
Patients | 2 | 2023 | 907 | 0.220 |
Why?
|
Aged | 23 | 2024 | 169310 | 0.200 |
Why?
|
Blood Transfusion | 2 | 2020 | 1301 | 0.200 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 125 | 0.190 |
Why?
|
Focus Groups | 2 | 2020 | 1415 | 0.190 |
Why?
|
Leukemia | 2 | 2022 | 1522 | 0.190 |
Why?
|
Purines | 2 | 2021 | 607 | 0.190 |
Why?
|
Quality of Health Care | 4 | 2018 | 4331 | 0.180 |
Why?
|
United States | 10 | 2023 | 72340 | 0.180 |
Why?
|
Male | 29 | 2024 | 360846 | 0.180 |
Why?
|
Female | 31 | 2024 | 392705 | 0.180 |
Why?
|
Attitude to Death | 1 | 2023 | 400 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1640 | 0.170 |
Why?
|
Lymphoma, Follicular | 1 | 2023 | 457 | 0.160 |
Why?
|
Multivariate Analysis | 4 | 2017 | 12059 | 0.160 |
Why?
|
Salvage Therapy | 2 | 2022 | 1263 | 0.160 |
Why?
|
Factor Analysis, Statistical | 1 | 2021 | 999 | 0.150 |
Why?
|
Bereavement | 1 | 2022 | 308 | 0.150 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2220 | 0.140 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58984 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9280 | 0.130 |
Why?
|
Myelodysplastic Syndromes | 2 | 2016 | 1394 | 0.130 |
Why?
|
Goals | 1 | 2021 | 711 | 0.130 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2016 | 92 | 0.130 |
Why?
|
Middle Aged | 18 | 2024 | 220921 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 343 | 0.120 |
Why?
|
Adult | 14 | 2023 | 221210 | 0.110 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12463 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2019 | 909 | 0.110 |
Why?
|
Autoimmunity | 1 | 2021 | 1356 | 0.110 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13642 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10194 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 422 | 0.110 |
Why?
|
Research | 1 | 2021 | 1982 | 0.100 |
Why?
|
Hematology | 1 | 2016 | 243 | 0.100 |
Why?
|
Mutation | 2 | 2013 | 30053 | 0.100 |
Why?
|
Logistic Models | 3 | 2016 | 13255 | 0.100 |
Why?
|
Vincristine | 1 | 2014 | 1036 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26129 | 0.100 |
Why?
|
Anemia, Aplastic | 1 | 2013 | 230 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2016 | 4016 | 0.090 |
Why?
|
Anxiety Disorders | 1 | 2022 | 2720 | 0.090 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 1600 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.080 |
Why?
|
Vidarabine | 2 | 2021 | 336 | 0.080 |
Why?
|
Prednisone | 1 | 2014 | 1563 | 0.080 |
Why?
|
Life Expectancy | 1 | 2016 | 1243 | 0.080 |
Why?
|
Intensive Care Units | 2 | 2019 | 3744 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6228 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2018 | 1796 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1367 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2016 | 993 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2016 | 1333 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2697 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4853 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1118 | 0.080 |
Why?
|
Cohort Studies | 4 | 2016 | 41495 | 0.080 |
Why?
|
Neoplasm, Residual | 2 | 2023 | 1008 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3605 | 0.070 |
Why?
|
Doxorubicin | 1 | 2014 | 2224 | 0.070 |
Why?
|
Information Dissemination | 1 | 2016 | 1126 | 0.070 |
Why?
|
Bone Marrow | 2 | 2020 | 2911 | 0.070 |
Why?
|
Patient Transfer | 1 | 2014 | 794 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1069 | 0.070 |
Why?
|
Age Factors | 4 | 2020 | 18399 | 0.070 |
Why?
|
Critical Illness | 2 | 2017 | 2723 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3206 | 0.070 |
Why?
|
Anxiety | 1 | 2022 | 4573 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3606 | 0.070 |
Why?
|
Attitude of Health Personnel | 2 | 2021 | 3889 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 2004 | 0.070 |
Why?
|
Odds Ratio | 2 | 2016 | 9647 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11120 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1844 | 0.060 |
Why?
|
Pyrroles | 1 | 2012 | 1125 | 0.060 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2012 | 801 | 0.060 |
Why?
|
Health Expenditures | 1 | 2018 | 2366 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4111 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 9177 | 0.060 |
Why?
|
Sex Factors | 2 | 2016 | 10554 | 0.060 |
Why?
|
Cytarabine | 2 | 2020 | 698 | 0.060 |
Why?
|
Time Factors | 2 | 2016 | 39969 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7828 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1833 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6484 | 0.060 |
Why?
|
Mental Disorders | 1 | 2023 | 6845 | 0.050 |
Why?
|
Sepsis | 1 | 2017 | 2585 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 398 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2048 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4758 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2023 | 6815 | 0.050 |
Why?
|
Comorbidity | 1 | 2015 | 10508 | 0.050 |
Why?
|
Young Adult | 3 | 2022 | 59260 | 0.040 |
Why?
|
Advance Directives | 1 | 2021 | 249 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10721 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 88326 | 0.040 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2332 | 0.040 |
Why?
|
Retrospective Studies | 7 | 2024 | 80647 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2012 | 4317 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2012 | 3615 | 0.030 |
Why?
|
Uncertainty | 1 | 2021 | 754 | 0.030 |
Why?
|
Enterococcus faecalis | 1 | 2017 | 245 | 0.030 |
Why?
|
Child | 2 | 2022 | 80158 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Cytogenetics | 1 | 2016 | 198 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2020 | 64685 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1065 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 226 | 0.030 |
Why?
|
Data Collection | 1 | 2023 | 3322 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10090 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 712 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
Antigens, CD | 2 | 2014 | 4001 | 0.030 |
Why?
|
Hematinics | 1 | 2016 | 282 | 0.030 |
Why?
|
Milk, Human | 1 | 2017 | 486 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2017 | 664 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6938 | 0.030 |
Why?
|
Daunorubicin | 1 | 2012 | 157 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2016 | 0.020 |
Why?
|
Ilium | 1 | 2012 | 155 | 0.020 |
Why?
|
Sternum | 1 | 2012 | 175 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1827 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2012 | 407 | 0.020 |
Why?
|
Clone Cells | 1 | 2014 | 1659 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 5485 | 0.020 |
Why?
|
Leucovorin | 1 | 2012 | 643 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3878 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1668 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1869 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2014 | 1186 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1393 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2012 | 877 | 0.020 |
Why?
|
Safety | 1 | 2012 | 1149 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4580 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4652 | 0.020 |
Why?
|
Infant, Premature | 1 | 2017 | 2107 | 0.020 |
Why?
|
Fluorouracil | 1 | 2012 | 1642 | 0.020 |
Why?
|
Iron | 1 | 2016 | 1793 | 0.020 |
Why?
|
Income | 1 | 2016 | 1877 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5073 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2557 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 2397 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.020 |
Why?
|
Self Report | 1 | 2018 | 3725 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1862 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2523 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2521 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2811 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15733 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3617 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3093 | 0.010 |
Why?
|
Massachusetts | 1 | 2016 | 8833 | 0.010 |
Why?
|
Health Status | 1 | 2016 | 4077 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10774 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7581 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3802 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7968 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6180 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9420 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10212 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7406 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10451 | 0.010 |
Why?
|
Survival Rate | 1 | 2012 | 12723 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16592 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 26202 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22176 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 23996 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 74213 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2012 | 39106 | 0.010 |
Why?
|
Child, Preschool | 1 | 2013 | 42232 | 0.010 |
Why?
|
Mice | 1 | 2016 | 81539 | 0.000 |
Why?
|
Animals | 1 | 2016 | 168475 | 0.000 |
Why?
|